(Seoul=Yonhap Infomax) Su In Jeong = Samsung Biologics Co., South Korea's leading biopharmaceutical contract manufacturer, announced on the 25th that it has promoted two executive vice presidents and four senior vice presidents as part of its 2026 executive appointments.


Kim Hee-jung, Executive Vice President, Operations Center DS, Samsung Biologics
[Source: Samsung Biologics]


Jeong Hyeong-nam, Executive Vice President, Head of Bio Research Institute, Samsung Biologics
[Source: Samsung Biologics]


The newly promoted executive vice presidents are Kim Hee-jung and Jeong Hyeong-nam.

Kim, who now serves as Executive Vice President of Operations Center DS, was recognized for establishing a stable drug substance (DS) production system despite ramping up new plants and expanding manufacturing capacity. Jeong, head of the Samsung Biologics Bio Research Institute, was credited for driving innovation in the antibody-drug conjugate (ADC) business, launching new services, and strengthening the competitiveness of the contract development organization (CDO) business through proprietary antibody technology development.

The four newly promoted senior vice presidents are An So-yeon, Yu Dong-seon, Cha Young-pil, and Hwang Jun-ho.

An was acknowledged for achieving full-scale operation of Plant 4 ahead of schedule by optimizing production processes and timelines, contributing to increased sales through stable pharmaceutical production. Yu was recognized for enhancing technology transfer competitiveness by improving Manufacturing Science and Technology (MSAT) processes.

Cha and Hwang were newly appointed as senior vice presidents for their roles in advancing the Manufacturing Execution System (MES) and providing effective support for overall business operations, according to the company.

Samsung Biologics stated that this round of appointments reflects a strengthened performance- and competency-based HR policy aimed at establishing agile decision-making structures and bolstering future competitiveness amid a volatile global environment.

The company also highlighted the significance of these promotions, noting the appointment of the youngest female executives in its history, with An So-yeon promoted to senior vice president in her 30s and Kim Hee-jung to executive vice president in her 40s.

Following these regular executive appointments, Samsung Biologics plans to implement a company-wide organizational restructuring and additional personnel changes.

sijung@yna.co.kr

(End)

All content has been translated by AI.
Copyright © Yonhap Infomax Unauthorized reproduction and redistribution prohibited.